ProShares Ultra NASDAQ Biotechnology
34 hedge funds and large institutions have $13.8M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
26% more funds holding
Funds holding: 27 → 34 (+7)
0.43% less ownership
Funds ownership: 6.43% → 6% (-0.43%)
12% less capital invested
Capital invested by funds: $15.6M → $13.8M (-$1.87M)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
32% less call options, than puts
Call options by funds: $5.57M | Put options by funds: $8.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.73M |
| 2 |
VF
Virtu Financial
New York
|
+$1.53M |
| 3 |
HF
HRT Financial
New York
|
+$253K |
| 4 |
SW
SlateStone Wealth
Jupiter,
Florida
|
+$248K |
| 5 |
MC
Moors & Cabot
Boston,
Massachusetts
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.04M |
| 2 |
Jane Street
New York
|
-$629K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$581K |
| 4 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
-$423K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$135K |
BIB Hedge Fund Activity: Q2 2019 in Review
34 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2019, worth a combined $13.8M — down 12% from $15.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new BIB positions and 3 closed out — a net gain of 8 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $2.73M. The largest seller was Citadel Advisors, cutting an estimated $4.04M.
- 34 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2019, up from 27 in Q1 2019.
- Funds reported $13.8M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2019, down 12% quarter-over-quarter.
- 11 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2019 and 3 closed out, a net change of +8 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2019 was Tower Research Capital (TRC), an estimated $2.73M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2019 was Citadel Advisors, an estimated $4.04M sold.
Based on aggregated 13F filings for Q2 2019.